These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 31523783)
1. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. Karkhur S; Hasanreisoglu M; Vigil E; Halim MS; Hassan M; Plaza C; Nguyen NV; Afridi R; Tran AT; Do DV; Sepah YJ; Nguyen QD J Ophthalmic Inflamm Infect; 2019 Sep; 9(1):17. PubMed ID: 31523783 [TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-6 for noninfectious uveitis. Lin P Clin Ophthalmol; 2015; 9():1697-702. PubMed ID: 26392750 [TBL] [Abstract][Full Text] [Related]
3. Biological and Therapeutic Role of Interleukin-6 in Non-Infectious Uveitis: A Narrative Review. Cifuentes-González C; Mejía-Salgado G; Rojas-Carabali W; Diez-Bahamón LA; Garzón-Dangond JM; Janela B; de-la-Torre A; Agrawal R Ocul Immunol Inflamm; 2024 Oct; ():1-15. PubMed ID: 39404707 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition. Yang JY; Goldberg D; Sobrin L Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902105 [TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6 in autoimmune uveitis. Mesquida M; Molins B; Llorenç V; de la Maza MS; Adán A Autoimmun Rev; 2017 Oct; 16(10):1079-1089. PubMed ID: 28778705 [TBL] [Abstract][Full Text] [Related]
6. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757 [TBL] [Abstract][Full Text] [Related]
7. IL-6 blockade in the management of non-infectious uveitis. Lopalco G; Fabiani C; Sota J; Lucherini OM; Tosi GM; Frediani B; Iannone F; Galeazzi M; Franceschini R; Rigante D; Cantarini L Clin Rheumatol; 2017 Jul; 36(7):1459-1469. PubMed ID: 28528519 [TBL] [Abstract][Full Text] [Related]
8. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Thomas AS Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945 [TBL] [Abstract][Full Text] [Related]
9. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). Ramanan AV; Dick AD; Jones AP; Guly C; Hardwick B; Hickey H; Lee R; McKay A; Beresford MW; BMC Rheumatol; 2018; 2():4. PubMed ID: 30886955 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report. Burlo F; Tumminelli C; Pastore S; Stocco G; Curci D; Lucafò M; Tommasini A; Taddio A Pediatr Rheumatol Online J; 2023 Sep; 21(1):99. PubMed ID: 37700264 [TBL] [Abstract][Full Text] [Related]
11. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890 [TBL] [Abstract][Full Text] [Related]
12. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771 [TBL] [Abstract][Full Text] [Related]
14. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269 [TBL] [Abstract][Full Text] [Related]
15. Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. Xu C; Rafique A; Potocky T; Paccaly A; Nolain P; Lu Q; Iglesias-Rodriguez M; St John G; Nivens MC; Kanamaluru V; Fairhurst J; Ishii T; Maldonado R; Choy E; Emery P J Clin Pharmacol; 2021 May; 61(5):714-724. PubMed ID: 33314148 [TBL] [Abstract][Full Text] [Related]
16. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821 [TBL] [Abstract][Full Text] [Related]
17. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Mesquida M; Molins B; Llorenç V; Sainz de la Maza M; Adán A Ophthalmology; 2014 Dec; 121(12):2380-6. PubMed ID: 25204610 [TBL] [Abstract][Full Text] [Related]
19. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Bae SC; Lee YH Clin Rheumatol; 2018 Jun; 37(6):1471-1479. PubMed ID: 29404725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]